TABLE OF CONTENTS
Volume 79, Issue 1 (January 2006)
Pharmacodynamics and Drug Action |
Pharmacogenetics and Genomics |
Pharmacogenetics and Genomics |
Pharmacokinetics and Drug Disposition |
Clinical Trial
Commentaries
The 2005 Leon I. Goldberg Young Investigator Award Lecture: Development of thalidomide as an angiogenesis inhibitor for the treatment of androgen-independent prostate cancer
William D. Figg PharmD
Clin Pharmacol Ther 79: 1-8; doi:10.1016/j.clpt.2005.09.006
New insights into the mechanism of action of acetaminophen: Its clinical pharmacologic characteristics reflect its inhibition of the two prostaglandin H2 synthases
David M. Aronoff MD, John A. Oates MD and Olivier Boutaud PhD
Clin Pharmacol Ther 79: 9-19; doi:10.1016/j.clpt.2005.09.009
The endothelium, inflammation, and coagulation in sepsis
Christopher J. Boos MRCP, Patrick K. Y. Goon MRCS and Gregory Y. H. Lip MD
Clin Pharmacol Ther 79: 20-22; doi:10.1016/j.clpt.2005.10.004
Pharmacodynamics and Drug Action
Recombinant human antithrombin inhibits thrombin formation and interleukin 6 release in human endotoxemia
Judith M. Leitner MD, Christa Firbas MD, Florian B. Mayr MD, Rosemarie A. Reiter MD, Barbara Steinlechner MD and Bernd Jilma MD
Clin Pharmacol Ther 79: 23-34; doi:10.1016/j.clpt.2005.10.003
Evidence for morphine-independent central nervous opioid effects after administration of codeine: Contribution of other codeine metabolites
Jörn Lötsch MD, PhD, Carsten Skarke MD, Helmut Schmidt PhD, Maren Rohrbacher MD, Ute Hofmann PhD, Matthias Schwab MD and Gerd Geisslinger MD, PhD
Clin Pharmacol Ther 79: 35-48; doi:10.1016/j.clpt.2005.09.005
Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans
Michel Azizi MD, PhD, Alvine Bissery MSc, Séverine Peyrard MSc, Than Tam Guyene MD, Marie-Laure Ozoux PhD, Anne Floch MD and Joël Ménard MD
Clin Pharmacol Ther 79: 49-61; doi:10.1016/j.clpt.2005.09.011
Pharmacogenetics and Genomics
MDR1 gene polymorphisms and risk of gingival hyperplasia induced by calcium antagonists
Peter Meisel PhD, Jürgen Giebel PhD, Christiane Kunert-Keil PhD, Peter Dazert PhD, Heyo K. Kroemer PhD and Thomas Kocher MD
Clin Pharmacol Ther 79: 62-71; doi:10.1016/j.clpt.2005.09.008
Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action
Jörn Lötsch MD, Carsten Skarke MD, Johannes Wieting, Bruno Georg Oertel MSc, Helmut Schmidt PhD, Jürgen Brockmöller MD and Gerd Geisslinger MD, PhD
Clin Pharmacol Ther 79: 72-89; doi:10.1016/j.clpt.2005.09.010
Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients
Satohiro Masuda PhD, Maki Goto PhD, Sachio Fukatsu BS, Miwa Uesugi BS, Yasuhiro Ogura MD, Fumitaka Oike MD, Tetsuya Kiuchi MD, Yasutsugu Takada MD, Koichi Tanaka MD and Ken-ichi Inui PhD
Clin Pharmacol Ther 79: 90-102; doi:10.1016/j.clpt.2005.09.013
Pharmacogenetics and Genomics
A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants
Sarah C. Sim MSc, Carl Risinger PhD, Marja-Liisa Dahl MD, PhD, Eleni Aklillu PhD, Magnus Christensen MD, PhD, Leif Bertilsson PhD and Magnus Ingelman-Sundberg BScM, PhD
Clin Pharmacol Ther 79: 103-113; doi:10.1016/j.clpt.2005.10.002
Pharmacokinetics and Drug Disposition
Population analyses of amlodipine in patients living in the community and patients living in nursing homes
Dongwoo Kang PhD, Davide Verotta PhD and Janice B. Schwartz MD
Clin Pharmacol Ther 79: 114-124; doi:10.1016/j.clpt.2005.09.007
Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: In vitro and clinical studies
David J. Greenblatt, Lisa L. von Moltke, Elke Störmer Perloff, Yan Luo, Jerold S. Harmatz and Miguel A. Zinny
Clin Pharmacol Ther 79: 125-133; doi:10.1016/j.clpt.2005.09.014
Pharmacokinetic study of memantine in healthy and renally impaired subjects
Antonia Periclou PhD, Daniel Ventura PhD, Niranjan Rao PhD and Wattanaporn Abramowitz PhD
Clin Pharmacol Ther 79: 134-143; doi:10.1016/j.clpt.2005.10.005
Clinical Trial
Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: A crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19
Tomohiko Shimatani MD, PhD, Masaki Inoue MD, PhD, Tomoko Kuroiwa MS, Jing Xu MD, Hiroshi Mieno MD, PhD, Masuo Nakamura MD and Susumu Tazuma MD, PhD
Clin Pharmacol Ther 79: 144-152; doi:10.1016/j.clpt.2005.09.012
